AOD-9604

AOD-9604 (Advanced Obesity Drug, also known as hGH Fragment 176-191) is a synthetic 16-amino-acid peptide based on the C-terminal region of human growth hormone with an added tyrosine residue at the N-terminus for stability. It was developed in the 1990s at Monash University in Australia by Frank Ng and colleagues and licensed to Metabolic Pharmaceuticals for clinical development.

Full-length human growth hormone has multiple biological effects including stimulation of IGF-1 production, glucose regulation, lipolysis, and tissue growth. The C-terminal 176-191 fragment was identified as the region primarily responsible for the lipolytic effect, separate from the rest of the hormone's biology. The tyrosine modification at the N-terminus improves stability. The theoretical advantage: fat metabolism effects without IGF-1 stimulation or glucose increase.

The Australian Therapeutic Goods Administration has approved AOD-9604 as a Food and Beverage ingredient rather than a pharmaceutical drug, a regulatory positioning that reflects the failed Phase 2b efficacy data. No major regulator has approved AOD-9604 as a weight-loss drug.

The mechanism is based on selective lipolysis stimulation through pathways downstream of growth hormone signaling, without engaging the full GH receptor cascade.

Receptor-independent lipolysis. AOD-9604 does not bind the growth hormone receptor with high affinity. It appears to stimulate lipolysis through alternative pathways including beta-3 adrenergic receptor modulation and direct effects on adipose tissue mitochondrial activity.

Fatty acid oxidation enhancement. Animal studies report increased fatty acid release from adipose tissue stores and increased fatty acid oxidation in skeletal muscle.

Reduced lipogenesis. Inhibition of new fat storage in adipose tissue.

No IGF-1 stimulation, no glucose change. Unlike full-length GH, AOD-9604 does not appear to raise IGF-1 or impair glucose tolerance. This is the proposed safety advantage.

The pharmacokinetic profile shows approximately 40 percent oral bioavailability in animal models with a serum half-life of approximately 4 minutes.

The Phase 2b Trial Failure

The pivotal trial was the OPTIONS Study, a Phase 2b randomized double-blind placebo-controlled trial in approximately 300 obese patients in 2006 to 2007. Participants received oral AOD-9604 (0.25, 0.5, or 1 mg daily) or placebo for 24 weeks. The trial failed to meet its primary endpoint.

The earlier Phase 2 trial had reported a 2 kg weight loss more than placebo over a 12-week period. That signal did not replicate at the larger Phase 2b scale. Metabolic Pharmaceuticals discontinued obesity development in 2007 based on the Phase 2b results.

The Evidence-Marketing Gap

Despite the failed Phase 2b trial, AOD-9604 continues to be marketed by weight-loss clinics, telehealth wellness platforms (often combined with sermorelin, semaglutide, or other agents), and online research-chemical vendors as a fat-loss peptide.

The honest evidence picture: AOD-9604 has not been shown to produce clinically meaningful weight loss versus placebo in adequately powered human trials. For comparison, semaglutide produces approximately 15 percent mean weight loss over 68 weeks in placebo-controlled trials. Tirzepatide produces 20+ percent. AOD-9604 failed to produce statistically significant weight loss above placebo in its largest human trial.

Regulatory Status

Australia. GRAS status as Food and Beverage ingredient. United States. No FDA drug approval. Added to FDA Category 2 bulks list on September 29, 2023. EU and UK. No EMA or MHRA authorization. WADA status. On the Prohibited List under section S2.

The pivotal OPTIONS Phase 2b trial by Metabolic Pharmaceuticals tested oral AOD-9604 at 0.25, 0.5, and 1 mg daily for 24 weeks in approximately 300 obese patients. The primary endpoint was weight loss at 12 weeks. The trial failed to meet its primary endpoint.

Earlier Phase 1 and Phase 2 trials tested oral and subcutaneous AOD-9604 at doses ranging from 0.1 to 3 mg daily, with reported 40 percent oral bioavailability in animals. Subcutaneous injection at 250 to 500 mcg daily has been used in current wellness-clinic protocols. Both routes have been investigated.

AOD-9604 has no FDA approval as a weight-loss drug. The compound was added to the FDA Category 2 bulks list on September 29, 2023, restricting US compounding pharmacy preparation. Australian TGA has approved AOD-9604 as a Food and Beverage ingredient rather than a pharmaceutical drug, which reflects the failed Phase 2b efficacy data combined with the favorable safety profile.

The AOD-9604 safety database is the strong part of the molecule's evidence base. Six randomized double-blind placebo-controlled trials across more than 900 participants reported:

• No serious adverse events at the doses tested.
• No clinically meaningful changes in IGF-1, distinguishing AOD-9604 from GH replacement therapy and from GHRH/GHRP class peptides.
• No clinically meaningful glucose increase or impaired insulin sensitivity.
• Mild gastrointestinal effects reported at low rates.
• Mild injection-site reactions with subcutaneous administration.
• No tolerance development to the lipolytic effects in studies of up to 24 weeks.

The clean safety profile is what supports the Australian Food and Beverage classification. It does not support the weight-loss claims that drive most adult use.

Semaglutide and tirzepatide. Both have FDA approval for chronic weight management with Phase 3 efficacy data showing 15 to 22 percent mean weight loss. AOD-9604 does not have comparable Phase 3 efficacy data. The gap is fundamental.

Sermorelin and other GH secretagogues. These work by stimulating endogenous growth hormone release, which has different downstream effects from selective fat metabolism. They are often discussed in similar clinical settings but are not direct mechanistic alternatives.

Tesamorelin has FDA approval for HIV-associated lipodystrophy with Phase 3 data showing 15 percent visceral adipose tissue reduction. Different mechanism and patient population, but it has the Phase 3 backing that AOD-9604 lacks.

For the legitimate weight-loss indication in adults with obesity, AOD-9604 is not a competitive option compared with the GLP-1 class.